公开(公告)号：US20150104819A1

公开(公告)日：2015-04-16

申请号：US14404134

申请日：2013-03-07

Applicant: STC.UNM ,  THE JOHNS HOPKINS UNIVERSITY

Inventor： Graham Timmins ,  Seong Choi ,  Zachary Sharp ,  Viorel Atudorei ,  Mamoudou Maiga ,  William Bishai

IPC: C12Q1/04 ,  C12Q1/28

CPC classification number: C12Q1/04 ,  C12Q1/28 ,  C12Q2304/48 ,  G01N33/5695 ,  G01N33/60 ,  G01N2333/35

Abstract: The present invention is directed to methods of diagnosing the presence or absence of a bacterial infection in a patient, in particular, a tuberculosis infection, by measuring exhaled, isotopically labeled nitrogen gas after administration of isotopic ally labeled isoniazid.

Abstract translation: 本发明涉及通过在施用同位素标记的异烟肼之后测量呼出的同位素标记的氮气来诊断患者中细菌感染的存在或不存在，特别是结核病感染的方法。

公开(公告)号：US20200237687A1

公开(公告)日：2020-07-30

申请号：US16778220

申请日：2020-01-31

Applicant: STC.UNM

Inventor： Graham Timmins ,  Vojo P. Deretic

IPC: A61K31/137 ,  A61K45/06 ,  A61K35/00 ,  A61K51/04 ,  A61K9/00 ,  C07C213/08 ,  A61K31/136 ,  A61P31/04 ,  A61P11/00 ,  C07C215/68 ,  A61K31/395 ,  C07C215/42 ,  C07B59/00 ,  A61P31/06 ,  A61K45/00

Abstract: The present invention is directed to 13C and/or 2H isotope enhanced ambroxol (“isotope enhanced ambroxol”) and its use in the treatment of autophagy infections, especially mycobacterial and other infections, disease states and/or conditions of the lung, such as tuberculosis, especially including drug resistant and multiple drag resistant tuberculosis. Pharmaceutical compositions comprising isotope enhanced ambroxol, alone or in combination with an additional bioactive agent, especially rifamycin antibiotics, including an additional autophagy modulator (an agent which is active to promote or inhibit autophagy), thus being useful against, an autophagy mediated disease state and/or condition), especially an antophagy mediated disease state and/or condition which occurs in the lungs, for example, a Mycobacterium infection. Chronic Obstructive Pulmonary Disease (COPD), asthma, pulmonary fibrosis, cystic fibrosis, Sjogren's disease and lung cancer (small cell and non-small cell lung cancer, among other disease states and/or conditions, especially of the lung. Methods of treating autophagy disease states and/or conditions, especially including autophagy disease states or conditions which occur principally in the lungs of a patient represent a further embodiment of the present invention. An additional embodiment includes methods of synthesizing compounds according to the present invention as otherwise disclosed herein.

公开(公告)号：US20180296505A1

公开(公告)日：2018-10-18

申请号：US16015415

申请日：2018-06-22

Applicant: STC.UNM

Inventor： Graham Timmins ,  Seong Won Choi

IPC: A61K31/16 ,  A61K9/00 ,  A61K31/4965 ,  A61K45/06

Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.

公开(公告)号：US20170056345A1

公开(公告)日：2017-03-02

申请号：US15119563

申请日：2015-02-18

Applicant: STC.UNM

Inventor： Graham Timmins ,  Seong Won Choi

IPC: A61K31/16 ,  A61K9/00 ,  A61K45/06 ,  A61K31/4965

CPC classification number: A61K31/16 ,  A61K9/0075 ,  A61K31/4965 ,  A61K45/06 ,  A61K2300/00

Abstract: In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.

Abstract translation: 在一个实施方案中，本发明提供了治疗患有或被怀疑患有分枝杆菌感染的受试者的方法，所述方法包括向受试者施用治疗有效量的脲酶抑制剂，任选地与一种 或更多的抗分枝杆菌剂。